



ELSEVIER

Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

## Free Radical Biology and Medicine

journal homepage: [www.elsevier.com/locate/freeradbiomed](http://www.elsevier.com/locate/freeradbiomed)

## Original Contribution

## Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment

Eugenio Barone<sup>a,b,1</sup>, Fabio Di Domenico<sup>a,c,1</sup>, Rukhsana Sultana<sup>a</sup>, Raffaella Coccia<sup>c</sup>, Cesare Mancuso<sup>b</sup>, Marzia Perluigi<sup>c</sup>, D. Allan Butterfield<sup>a,\*</sup><sup>a</sup> Department of Chemistry, Center of Membrane Sciences and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506-0055, USA<sup>b</sup> Institute of Pharmacology, Catholic University School of Medicine, 00168 Rome, Italy<sup>c</sup> Department of Biochemical Sciences, Sapienza University of Rome, 00185 Rome, Italy

## ARTICLE INFO

## Article history:

Received 10 December 2011

Received in revised form

7 February 2012

Accepted 19 March 2012

Available online 17 April 2012

## Keywords:

Alzheimer disease

Heme oxygenase

Mild cognitive impairment

Oxidative stress

Free radicals

## ABSTRACT

Alzheimer disease (AD) is a neurodegenerative disorder characterized by progressive cognitive impairment and neuropathology. Oxidative and nitrosative stress plays a principal role in the pathogenesis of AD. The induction of the heme oxygenase-1/biliverdin reductase-A (HO-1/BVR-A) system in the brain represents one of the earliest mechanisms activated by cells to counteract the noxious effects of increased reactive oxygen species and reactive nitrogen species. Although initially proposed as a neuroprotective system in AD brain, the HO-1/BVR-A pathophysiological features are under debate. We previously reported alterations in BVR activity along with decreased phosphorylation and increased oxidative/nitrosative posttranslational modifications in the brain of subjects with AD and those with mild cognitive impairment (MCI). Furthermore, other groups proposed the observed increase in HO-1 in AD brain as a possible neurotoxic mechanism. Here we provide new insights about HO-1 in the brain of subjects with AD and MCI, the latter condition being the transitional phase between normal aging and early AD. HO-1 protein levels were significantly increased in the hippocampus of AD subjects, whereas HO-2 protein levels were significantly decreased in both AD and MCI hippocampi. In addition, significant increases in Ser-residue phosphorylation together with increased oxidative posttranslational modifications were found in the hippocampus of AD subjects. Interestingly, despite the lack of oxidative stress-induced AD neuropathology in cerebellum, HO-1 demonstrated increased Ser-residue phosphorylation and oxidative posttranslational modifications in this brain area, suggesting HO-1 as a target of oxidative damage even in the cerebellum. The significance of these findings is profound and opens new avenues into the comprehension of the role of HO-1 in the pathogenesis of AD.

© 2012 Elsevier Inc. All rights reserved.

## Introduction

Increased oxidative and nitrosative stress represents one of the main mechanisms involved in the pathogenesis of neurodegenerative disorders such as Alzheimer disease (AD), which exhibits a large impairment of neuronal structure and molecular pathways due to oxidative stress-induced posttranslational modifications on both proteins and lipids [1,2].

AD is an age-related neurodegenerative disorder characterized histopathologically by the presence of senile plaques, neurofibrillary

tangles (NFTs), and synapse loss in selected brain regions [3,4] and clinically by memory loss and dementia [5]. The main component of senile plaques is amyloid  $\beta$ -peptide (A $\beta$ ), a 40- to 42-amino-acid peptide derived by the proteolytic cleavage of amyloid precursor protein through the activity of  $\beta$ - and  $\gamma$ -secretases [4]. Although A $\beta$ (1–42) is a neurotoxic peptide that exists in both soluble (monomers, oligomers, and protofibrils) and insoluble (fibrils) forms [6], recent studies suggested that the small oligomers, rather than A $\beta$  fibrils, are the actual toxic species of this peptide [7–10], being responsible for oxidative/nitrosative-induced damage in the brain [1,11–13]. Amnesic mild cognitive impairment (MCI) is considered the transitional phase between normal aging and early AD [14]. MCI shares pathological features with AD, such as A $\beta$  and NFT accumulation in the neocortex and medial temporal lobe [14,15], which leads to elevated pro-oxidant status [16] and clinical aspects including memory loss [16]. However, MCI subjects are not characterized by dementia, with subjects being able to perform normal activities of daily living [17].

**Abbreviations:** 3-NT, 3-nitrotyrosine; AD, Alzheimer disease; HNE, 4-hydroxy-2-nonenal; HO, heme oxygenase; MCI, mild cognitive impairment; PC, protein carbonyls; pSer, phosphoserine; pThr, phosphothreonine; pTyr, phosphotyrosine

\* Corresponding author. Fax: +1 859 259 5876.

E-mail address: [dabcns@uky.edu](mailto:dabcns@uky.edu) (D.A. Butterfield).

<sup>1</sup> These authors contributed equally to this work.

Under conditions of prolonged oxidative and nitrosative stress the brain reacts by upregulating genes involved in cell stress response processes to limit neuronal damage [18,19]. The heme oxygenase/biliverdin reductase (HO/BVR) system, whose upregulation is one of the earlier events in AD, plays a crucial role in the adaptive response to stress [20]. Heme oxygenase is a microsomal enzyme that exists in two main isoforms: the inducible HO-1 and the constitutive HO-2 [21]. Heme oxygenase-1, also known as heat shock protein-32, is induced by various stimuli, including reactive oxygen and nitrogen species, ischemia, heat shock, bacterial lipopolysaccharide, hemin, and the neuroprotective agent leteprinim potassium (Neotrofin), and is primarily involved in the cell stress response [21–23]. Conversely HO-2 is responsive to developmental factors and adrenal glucocorticoids and works as an intracellular sensor of oxygen, carbon monoxide, and nitric oxide [21,23]. Furthermore, our group demonstrated an upregulation of both HO-1 and HO-2 in the brain of aged dogs after atorvastatin treatment [24]. Heme oxygenase catalyzes the oxidation of the  $\alpha$ -meso-carbon bridge of heme moieties, resulting in equimolar amounts of the pleiotropic gaseous neuromodulator carbon monoxide (CO), ferrous iron, and biliverdin-IX $\alpha$ . Biliverdin-IX $\alpha$  is further reduced by the cytosolic enzyme biliverdin reductase-A (BVR-A) into the powerful antioxidant bilirubin-IX $\alpha$ , the final product of heme catabolism [25–27]. It is noteworthy that the activity of both HO-1 and BVR-A was demonstrated to be regulated by the phosphorylation of serine/threonine/tyrosine residues [28,29].

In the central nervous system HO-2 is expressed in neuronal populations in almost all brain areas [21], whereas the inducible isoform is present at low levels in scattered groups of neurons, including the ventromedial and paraventricular nuclei of the hypothalamus [21,23]. HO-1 is also found in glial cells, where its expression can be induced by oxidative stress [30]. Similarly, BVR-A is coexpressed with HO-1 and/or HO-2 in cells of the rat brain that express these enzymes under normal conditions. BVR-A is also found in regions and cell types that can express heat-shock-inducible HO-1 [31].

Recent studies raised questions about the activation of the HO-1/BVR-A system in neurodegenerative disorders, opening a debate on its real pathophysiological and clinical significance. In particular, lately, our group has reported alterations in BVR activity related to decreased phosphorylation and increased oxidative/nitrosative posttranslational modifications in the brain of AD and MCI subjects [32,33]. Furthermore, Hui et al., in a recent work, provided a potential pathway to explain tau aggregation,

through a mechanism involving excessive iron production mediated by HO-1 overexpression, which in turn induces tau phosphorylation [34]. In addition, Schipper et al. showed that targeted suppression of glial HO-1 hyperactivity may prove to be a rational and effective neurotherapeutic intervention in AD [35]. In this scenario, a deeper level of analysis is required to elucidate the contribution of the HO/BVR system to neurodegenerative disorders.

Based on the evidence that, despite an upregulation of the HO-1/BVR-A system, a substantial protection against oxidative and nitrosative stress is not observed in AD brain, we hypothesized that, as for BVR-A, even HO-1 could be a target of oxidative/nitrosative stress. The aim of this study was to investigate HO-1 protein levels along with (i) phosphorylation- and (ii) oxidative/nitrosative stress-induced posttranslational modifications in both hippocampus and cerebellum of subjects with AD or MCI.

## Materials and methods

### Chemicals

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. Nitrocellulose membranes and the electrophoresis transfer system Trans-Blot semidry transfer cell were obtained from Bio-Rad (Hercules, CA, USA). Anti-mouse and anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody and ECL Plus Western blot detection reagents were obtained from GE Healthcare Bio-Sciences (Piscataway, NJ, USA).

### Subjects

Frozen hippocampal and cerebellar samples ( $n=6$  each) from well-characterized subjects with AD and MCI and respective age-matched controls (Table 1A and B) were obtained from the University of Kentucky Rapid Autopsy Program of the Alzheimer's Disease Clinical Center (UK ADC) with a postmortem interval within the range 1.75–5.75 h for AD and MCI patients and age-matched control subjects. All the subjects were longitudinally followed and underwent annual neuropsychological testing and neurological and physical examinations. Control subjects were without history of dementia or other neurological disorders and with intact activities of daily living (ADLs), and they underwent annual mental status testing and semiannual physical and neurological exams as part of the UK ADC normal volunteer

**Table 1**

<i>(A) Demographic information on amnesic MCI subjects and their respective age-matched controls</i>		
Subject demographics	Controls	MCI
Number of subjects	6	6
Sex	2 M, 4 F	2 M, 4 F
Age (years (range))	82 (74–93)	89 (82–99)
Brain weight (g (range))	1204 (1080–1315)	1102 (930–1200)
Postmortem interval (h)	1.75–4.00	2.00–5.00
Braak stage	I–II	III–V
<i>(B) Demographic information on AD subjects and their respective age-matched controls</i>		
Subject demographics	Control (AD)	AD
Number of subjects	6	6
Sex	5 M, 1 F	2 M, 4 F
Age (years (range))	81 (72–87)	85 (80–92)
Brain weight (g (range))	1219 (1020–1410)	1104 (835–1260)
Postmortem interval (h)	2.00–3.75	2.00–5.75
Braak stage	I–III	V–VI

The values reported are the averages of six samples.

longitudinal aging study. The control subjects showed no significant histopathological alterations and the Braak score was within the range I–II for the MCI age-matched controls and I–III for the AD age-matched controls. Patients diagnosed with MCI met the criteria described by Petersen [14], which included a memory complaint supported by an informant, objective memory test impairment (age- and education-adjusted), general normal global intellectual function, intact ADLs, Clinical Dementia Rating score of 0.0–0.5, no dementia, and a clinical evaluation that revealed no other cause for memory decline. AD patient diagnosis was made according to criteria developed by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association [36]. All AD patients displayed progressive intellectual decline. The Braak scores were within the range III–V and V–VI for MCI and AD patients, respectively.

### Sample preparation

Brain tissue samples (hippocampus and cerebellum) from control, MCI, and AD subjects were sonicated in Media 1 lysis buffer (pH 7.4) containing 0.32 M sucrose, 0.10 mM Tris–HCl (pH 8.8), 0.10 mM MgCl<sub>2</sub>, 0.08 mM EDTA, proteinase inhibitors leupeptin (0.5 mg/ml), pepstatin (0.7 µg/ml), aprotinin (0.5 mg/ml), and phenylmethanesulfonyl fluoride (40 µg/ml) and phosphatase inhibitor cocktail. Because the phosphorylation of serine residues by specific kinases (e.g., Akt/PKB) is involved in HO-1 activity [28], kinase inhibitors could interfere with such activity. For this reason, kinase inhibitors were not included in Media 1 lysis buffer. Homogenates were centrifuged at 14,000g for 10 min to remove debris. Protein concentration in the supernatant was determined by the Pierce BCA method (Pierce, Rockford, IL, USA).

### Western blot analysis

For the evaluation of HO-1 and HO-2 protein levels, 50 µg of total protein of brain homogenate was denatured in sample buffer for 5 min at 100 °C and then separated on 12% precast Criterion gels (Bio-Rad) by electrophoresis at 100 mA for 2 h in Mops buffer (Bio-Rad) in a Bio-Rad apparatus. For the evaluation of HO-1 posttranslational modifications, 150 µg of total protein of brain homogenate was used, as described below. The proteins from the gels were then transferred to a nitrocellulose membrane using the Trans-Blot semi-dry transfer cell at 20 mA for 2 h. Subsequently, the membranes were blocked at 4 °C for 1 h with fresh blocking buffer made of 3% bovine serum albumin in phosphate-buffered saline (PBS) containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST). The membranes were incubated at room temperature in PBST for 2 h with the following primary antibodies, as separate experiments: anti-HO-1 (Stressgen, Ann Arbor, MI, USA, dilution 1:1000), anti-HO-2 (Stressgen, dilution 1:1000), anti-phosphoserine (Zymed, Invitrogen, Camarillo, CA, USA, dilution 1:250), anti-phosphothreonine (Zymed, dilution 1:250), anti-phosphotyrosine (Zymed, dilution 1:1000), anti-nitrotyrosine (3-NT; Sigma-Aldrich, dilution 1:100), anti-dinitrophenylhydrazine (DNP) protein adducts (Millipore, Billerica, MA, USA, dilution 1:100), anti-4-hydroxy-2-nonenal (HNE; Alpha Diagnostic International, San Antonio, TX, USA, dilution 1:100), and anti-β-actin (Sigma-Aldrich, dilution 1:2000). The membranes were then washed three times for 5 min with PBST followed by incubation with anti-mouse alkaline phosphatase or horseradish peroxidase-conjugated secondary antibody (1:3000) in PBST for 2 h at room temperature. Membranes were then washed three times in PBST for 5 min and developed using the 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium color-developing reagent for alkaline phosphatase secondary antibody or the ECL Plus WB detection reagents for horseradish

peroxidase-conjugated secondary antibody. Blots were dried and scanned in TIF format using Adobe Photoshop on a Canoscan 8800F (Canon) or STORM UV transilluminator (λ<sub>ex</sub> 470 nm, λ<sub>em</sub> 618 nm; Molecular Dynamics, Sunnyvale, CA, USA) for chemiluminescence. The images were quantified with ImageQuant TL 1D version 7.0 software (GE Healthcare). The optical density of the bands was calculated as volume (optical density × area) adjusted for the background.

### Immunoprecipitation

The immunoprecipitation procedure was performed as previously described [37] with modifications. Briefly, 150 µg of protein extracts was dissolved in 500 µl of RIPA buffer (10 mM Tris, pH 7.6; 140 mM NaCl; 0.5% NP-40 including protease inhibitors) and then incubated with 1 µg of anti-HO-1 antibody at 4 °C overnight. Immunocomplexes were collected by using protein A/G suspension for 2 h at 4 °C and washed five times with immunoprecipitation buffer. Immunoprecipitated HO-1 was recovered by resuspending the pellets in reducing SDS buffers and subjected to electrophoresis on 12% gels followed by Western blot analysis. The membranes were then stripped and reprobed using an anti-HO-1 antibody as described above. Total HO-1 was used as loading control according to [38,39].

### Postderivatization of protein

Samples were postderivatized with dinitrophenylhydrazine (DNPH) on the membrane and probed with anti-DNP antibody to identify the carbonylated proteins. The nitrocellulose membranes were equilibrated in solution A (20% (v/v) methanol and 80% (v/v) wash blot buffer (PBS solution containing 0.04% (v/v) Tween 20 and 0.10 M NaCl)) for 5 min, followed by incubation of membranes in 2 N HCl for 5 min. The proteins on blots were then derivatized in solution B (0.5 mM DNPH in 2 N HCl) for 10 min as described in [40]. The membranes were successively washed, 5 min each time, in 2 N HCl three times, wash blot buffer/methanol (50/50) five times, and finally wash blot buffer two times. The DNP adducts were detected immunochemically as described above.

### Statistical analysis


All statistical analysis was performed using a two-tailed Student *t* test. *P* < 0.05 was considered significantly different from control.

## Results

### HO-1 and HO-2 protein levels in hippocampus and cerebellum of subjects with AD or MCI

In 1995 Schipper and colleagues observed intense immunoreactivity of HO-1 in neurons of the hippocampus and temporal cortex of AD brain relative to age-matched control specimens [41]. In addition, we previously observed an increased expression of HO-1 together with a decreased expression of HO-2 in the inferior parietal lobule of AD brains, a region that showed elevated oxidative and nitrosative stress [42].

Before proceeding with the analysis of posttranslational modifications, we first analyzed HO-1 and HO-2 protein levels in our samples. In the hippocampus of AD subjects, HO-1 protein levels were significantly increased by 119% with respect to age-matched controls (Fig. 1a). Conversely, HO-2 protein levels were significantly decreased by 35% in the same brain area (Fig. 1b). With respect to MCI, a previous study from our group performed by



**Fig. 1.** Heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) protein levels in the hippocampus and cerebellum of subjects with Alzheimer disease (AD) and mild cognitive impairment (MCI). HO-1 protein levels in the hippocampus of (a) AD subjects; HO-2 protein levels in the hippocampus of (b) AD and (c) MCI subjects; HO-1 protein levels in the cerebellum of (d) AD subjects; HO-2 protein levels in the cerebellum of (e) AD and (f) MCI subjects. Representative gels are shown. Data are expressed as means  $\pm$  SD ( $n=6$  individual samples per group). \* $P < 0.05$  and \*\* $P < 0.01$  versus control.

using the same set of samples showed that HO-1 protein levels, in both hippocampus and cerebellum, were not significantly different from those observed in age-matched controls [43]. Here we extended the analysis to HO-2 protein levels, which showed a significant decrease by about 30% in the hippocampus of subjects with MCI (Fig. 1c). In cerebellum, HO-1 protein levels were decreased ( $\sim 38\%$ ) in AD subjects with respect to the matched controls (Fig. 1d), although this value did not reach statistical significance. No significant differences were found for HO-2 in the same brain area (Fig. 1e). Finally, no changes were observed in HO-2 protein levels in the cerebellum of MCI subjects with respect to the matched controls (Fig. 1f).

#### HO-1 phosphorylation modifications in the hippocampus and cerebellum of subjects with AD or MCI


In 2004 Salinas et al. demonstrated that human HO-1 can be phosphorylated at specific serine residues and such phosphorylation regulates the interaction with BVR as well as its own activity [28]. In contrast HO-2 has a nonphosphorylatable arginine instead of Ser [28]. For this reason, and because of the significant decrease in protein levels observed in AD and MCI hippocampi, HO-2 was not taken into account for the analysis of posttranslational modifications. To clarify if HO-1 undergoes phosphorylation modifications in the hippocampus and cerebellum of subjects with AD or MCI, we analyzed the levels of phosphoserine (pSer), phosphothreonine (pThr), and phosphotyrosine (pTyr) of HO-1.

As shown in Fig. 2a, pSer-HO-1 is significantly increased in the hippocampus of subjects with AD, whereas no changes were observed for pThr-HO-1 (Fig. 2b). Interestingly, no signal was obtained for pTyr-HO-1 (Fig. 2c), probably because of the lower number of Tyr residues in HO-1 with respect to Ser and Thr residues [44] or a lower involvement of Tyr phosphorylation. In the hippocampus of subjects with MCI no significant differences were observed for both pSer-HO-1 (Fig. 2d) and pThr-HO-1 (Fig. 2e) with respect to the matched controls. As for AD, no signal was obtained with regard to the analysis of pTyr-HO-1 in the hippocampus of subjects with MCI (data not shown). Finally, to evaluate whether changes observed for pSer-HO-1 levels were specific for hippocampal tissue, the same experiments were performed in the cerebellum. pSer-HO-1 is significantly increased by 21% (Fig. 3a) or 24% (Fig. 3b) in the cerebellum of subjects with AD or MCI, respectively.


#### Protein carbonyls (PC), protein-bound HNE, and 3-NT levels on HO-1 in the hippocampus and cerebellum of subjects with AD or MCI

To evaluate if HO-1 is a target for oxidative and nitrosative stress-induced posttranslational modifications, the levels of PC, protein-bound HNE, and 3-NT on HO-1 were evaluated in the hippocampus and cerebellum of subjects with AD or MCI. PC (Fig. 4a) and protein-bound HNE (Fig. 4b) on HO-1 were significantly increased by 30% and 52%, respectively, whereas no signal detection was observed for 3-NT (Fig. 4c) in the hippocampus of subjects with





**Fig. 2.** HO-1 phosphorylation on serine (pSer), threonine (pThr), and tyrosine (pTyr) residues in the hippocampus of subjects with AD and MCI. (a) pSer, (b) pThr, and (c) pTyr levels on HO-1 in the hippocampus of AD subjects. (d) pSer and (e) pThr levels on HO-1 in the hippocampus of MCI subjects. Representative gels are shown. Data are expressed as means  $\pm$  SD ( $n=6$  individual samples per group). \*\* $P < 0.01$  versus control.




**Fig. 3.** HO-1 phosphorylation on serine (pSer) residues in the cerebellum of subjects with AD and MCI. pSer levels on HO-1 in the cerebellum of (a) AD and (b) MCI subjects. Representative gels are shown. Data are expressed as means  $\pm$  SD ( $n=6$  individual samples per group). \* $P < 0.05$  versus control.

AD compared to age-matched controls. Together with the absence of pTyr-HO-1 signal detection, this last evidence probably results from the smaller contribution of Tyr residues in HO-1 posttranslational modifications. Interestingly, in the hippocampus of subjects with MCI no changes were found for PC (Fig. 4d), whereas a significant increase of 85% was observed in the levels of HNE-bound HO-1 (Fig. 4e). The analysis of cerebellar samples revealed no changes in the levels of PC in HO-1 on AD subjects with respect to the matched controls (Fig. 5a), whereas a significant increase of 36% in HNE-bound HO-1 (Fig. 5b) was observed. In contrast, in the cerebellum from subjects with MCI, we observed significantly increased levels

of PC (about 32%) in HO-1 (Fig. 5c), whereas no changes were demonstrated for levels of HNE-bound HO-1 (Fig. 5d).

## Discussion

Since it was discovered, the HO-1/BVR-A system has been considered a useful mechanism through which cells respond to oxidative/nitrosative stress insults, to prevent the impairment of cellular homeostasis. However, the effective contribution of HO-1/BVR-A system induction to cellular antioxidant defense is



**Fig. 4.** HO-1 oxidative and nitrosative posttranslational modifications in the hippocampus of subjects with AD and MCI. (a) Protein carbonyls (PC), (b) 4-hydroxy-2-nonenal (HNE), and (c) 3-nitrotyrosine (3-NT) levels on HO-1 in the hippocampus of AD subjects. (d) PC and (e) HNE levels on HO-1 in the hippocampus of MCI subjects. Representative gels are shown. Data are expressed as means  $\pm$  SD ( $n=6$  individual samples per group). \* $P < 0.05$  and \*\* $P < 0.01$  versus control.

currently under debate because a growing amount of evidence has questioned its protective role in neurodegenerative disorders.

In this paper our primary goal was to determine if evidence existed regarding HO-1 posttranslational modifications in the brain of AD and MCI subjects. We chose to investigate the hippocampus and cerebellum brain areas for this study because of their differential involvement in free radical-induced injury and pathology. Indeed, the hippocampus is broadly recognized as a main target of neurodegenerative damage during AD progression, presenting increased levels of oxidative stress, neuronal loss, and marked atrophy with respect to the whole brain. Conversely, the cerebellum is largely devoid of pathology and oxidative stress [45–47].

The first novel result provided by this study is the different profiles of HO-1 and HO-2 in the brain of subjects with AD or MCI. Previous data from Premkumar and colleagues have already shown different patterns of expression for HO-1 and HO-2 among neocortex, cerebellum, and cerebral vessel from AD subjects [48]. Here we extend the neurobiological behavior of HO-1 and HO-2 in the brain of AD and MCI subjects to include the following: (i) increase in HO-1 protein levels in another well-known brain area involved in AD pathology such as hippocampus, (ii) decrease in HO-2 protein levels in the same brain area, and (iii) no observed changes in HO-2 protein levels in cerebellum of MCI subjects. The increase in HO-1 in the hippocampus of AD subjects (Fig. 1a) is in good agreement with previous results [41,48] and could be easily explained by the elevated levels of oxidative stress observed in this brain area [21], whereas the decrease in HO-2 protein levels (Fig. 1b and c) is less obvious and represents an intriguing finding. Very few lines of evidence exist about the possibility of modulating HO-2 expression [24,49,50]. In the

present case we speculate that one possible explanation could come from the link between HO-2 and glucocorticoids. As previously demonstrated, the HO-2 gene possesses in its promoter region a consensus sequence for the glucocorticoid response element, which plays a main role in glucocorticoid-induced changes in HO-2 protein levels [51]. In 1994, Weber and colleagues demonstrated that corticosterone treatment decreased HO-2 protein levels in the hippocampus [49]. Furthermore, more recently, Chen et al. demonstrated that chronic restraint stress decreased HO-2 protein levels in hippocampal neurons and this stress-induced decrease in HO-2 protein levels may result from high corticosterone levels [50]. In addition, an impairment of the hypothalamic–pituitary–adrenal axis, which triggers the adrenal cortex to release glucocorticoids (cortisol in primates, corticosterone in mice and rats), was associated with AD and MCI pathogenesis [52–54]. In fact, glucocorticoids not only have been suggested to contribute to age-related loss of neurons in the hippocampus of rats [55], but also were shown to potentiate hippocampal damage induced by various noxious insults [56], including A $\beta$  peptide [57]. Thus, a conceivable justification for the significant decrease in HO-2 protein levels observed in the hippocampus of both AD and MCI subjects could be represented by corticosterone-induced decrease in the protein in this brain area [49].

With regard to HO-1, an interesting aspect of our work is the observed significant increase in Ser-residue phosphorylation along with oxidative posttranslational modifications in the hippocampus of AD subjects (Figs. 2a, 4b and c). Because HO-1 is a stress-inducible protein, and phosphorylation on Ser residues seems to be important for its activation [28], the increase in oxidative stress levels in the hippocampus of AD subjects could



parameter taken into account was the expression level of HO-1; thus it is not completely clear if the mechanisms proposed are linked to a specific signal-transduction pathway mediated by HO-1. It should be very interesting in the future to evaluate if, based on our results, the posttranslational modifications on HO-1 observed in AD and MCI brain could affect tau pathology positively or negatively.

With regard to MCI, the results from hippocampus add new elements to the comprehension of the contribution of the HO-1/BVR-A system to AD pathogenesis. Unlike BVR-A, whose expression levels were significantly increased even in the hippocampus of subjects with MCI [33], HO-1 protein levels did not present any differences [43]. This result could mean that the induction of each member of the HO-1/BVR-A system is not concomitant with the other, and probably the threshold levels of oxidative/nitrosative stress needed to induce HO-1 and BVR-A are different. Because of the pleiotropic functions of BVR-A in the maintenance of cellular homeostasis [29], it is plausible that the induction of BVR-A precedes that of HO-1. In contrast, the formation of HNE adducts on HO-1 (Fig. 4e), along with BVR-A nitration [32], is already evident in the hippocampus of subjects with MCI. In this light, despite the progressive increase in HO-1/BVR-A protein levels observed from MCI to AD [62], the impairment of the system probably is an early event in the pathogenesis and progression of the disease. A different behavior is shown for protein phosphorylation. We did not observe any significant difference in pSer-HO-1 in the hippocampus of MCI subjects with respect to age-matched controls (Fig. 2d), suggesting that the increase in the phosphorylation process occurs at a later stage of the disease.

We can speculate that increased Ser-residue phosphorylation along with increased protein levels could act as a compensatory mechanism to overcome the inactivation of HO-1 by oxidative damage. However, whether HO-1 functionality is in part restored after Ser-residue phosphorylation remains an unsolved question. To complete this intricate puzzle, the measure of HO-1 activity should be considered. However, it is not possible to single out the differential contributions of HO-1 and HO-2 to the generation of their products (i.e., CO, ferrous iron, and biliverdin) because of a lack of reliable selective inhibitors [27].

Another problem involves the possible repercussions of HO-1 upregulation on cell metabolism. As noted earlier, with respect to metabolism, HO activity is something of a double-edged sword [63,64]. The reduced availability of heme after HO-catalyzed degradation may provide useful antioxidant effects, but prolonged HO activation could produce low enough intracellular heme levels to be incapable of meeting the cell's metabolic requirements [63,64]. In fact, heme is the prosthetic group of hemoglobin, myoglobin, cytochromes, and several other important proteins, and excessively low concentrations can impair mitochondrial function and cell respiration. Furthermore, both CO and iron, which have physiological effects when produced under basal conditions, may become toxic if produced in excess [65–67].

In the scenario described above, the following considerations are in good agreement with the concerns about the neuroprotective or neurotoxic role of HO-1 in AD: (i) the failure to protect neurons against the deleterious effects of oxidative/nitrosative stress could be due to an impairment of HO-1, together with BVR-A, as suggested by our group [32,33], and (ii) phosphorylation is able to restore HO-1 functionality and as a consequence the sustained activation of HO-1 could be responsible, at least in part, for the observed increased oxidative stress, as well as tau phosphorylation, in the hippocampus of AD subjects, as suggested by other groups [34,35]. Thus, we suggest that the neuroprotective effects mediated by the HO/BVR-A system can be obtained only if the fine balance between the activity of HO-1 or HO-2 and that of BVR-A is maintained.

Another novel finding of this study regards the cerebellum, which has long been considered an internal control because of

minimal neuropathology [46]. Our results show a significant increase in HO-1 oxidation in the cerebellum of both MCI and AD subjects (Fig. 5b and c), although the elevations in HO-1 oxidation levels in a brain region with limited neuropathology may seem contradictory. However, recent studies suggest that disease-related changes could occur even in this brain area [68–70]. Furthermore, an increase in neurotoxic markers of lipid peroxidation (HNE or acrolein) and iron dyshomeostasis were found at an early stage of the disease, such as MCI or preclinical AD [46,70]. Thus, HO-1 could represent a likely target of oxidative damage even in the cerebellum. Finally, the observed increase in Ser-residue phosphorylation (Fig. 3a and b) along with oxidative modification in the cerebellum of MCI and AD subjects is in agreement with the explanation given for the hippocampus.

## Conclusion

In conclusion, our previous studies coupled with the current investigation show that the HO-1/BVR-A system is impaired in AD and MCI brain. In our opinion, it is no longer correct to measure only total HO-1 or BVR-A protein levels as an index to evaluate the involvement of these enzymes in the cell stress response because posttranslational modifications appear to play a main role in the regulation of the neuroprotective and/or metabolic activities of these proteins. The significance of these lines of evidence is profound, and ad hoc research to clarify the mechanisms involved in the regulation of HO-1/BVR-A system in AD and MCI is ongoing in our laboratory.

## Acknowledgments

This work was supported in part by an NIH Grant to D.A.B. (AG-05119). This work also was supported by a grant PRIN 2009 of the Italian Ministry of Education, University and Research to C.M. We are grateful to the Neuropathology Core of the University of Kentucky Alzheimer's Disease Clinical Center for providing well characterized specimens for this research.

## References

- [1] Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease. *Free Radical Biol. Med.* **23**:134–147; 1997.
- [2] Smith, M. A.; Richey, P. L.; Taneda, S.; Kutty, R. K.; Sayre, L. M.; Monnier, V. M.; Perry, G. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. *Ann. N. Y. Acad. Sci.* **738**:447–454; 1994.
- [3] Mirra, S. S. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. *Neurobiol. Aging* **18**:S91–S94; 1997.
- [4] Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. *N. Engl. J. Med.* **362**:329–344; 2010.
- [5] Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. *Lancet* **377**:1019–1031; 2011.
- [6] Mohamed, A.; Cortez, L.; de Chaves, E. P. Aggregation state and neurotoxic properties of Alzheimer  $\beta$ -amyloid peptide. *Curr. Protein Pept. Sci.* **12**:235–257; 2011.
- [7] Drake, J.; Link, C. D.; Butterfield, D. A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid  $\beta$ -peptide (1–42) in a transgenic *Caenorhabditis elegans* model. *Neurobiol. Aging* **24**:415–420; 2003.
- [8] Lambert, J. C.; Mann, D. M.; Harris, J. M.; Chartier-Harlin, M. C.; Cumming, A.; Coates, J.; Lemmon, H.; StClair, D.; Iwatsubo, T.; Lendon, C. The –48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased A $\beta$  load in brain. *J. Med. Genet.* **38**:353–355; 2001.
- [9] Oda, T.; Wals, P.; Osterburg, H. H.; Johnson, S. A.; Pasinetti, G. M.; Morgan, T. E.; Rozovsky, I.; Stine, W. B.; Snyder, S. W.; Holzman, T. F., et al. Clusterin (apoJ) alters the aggregation of amyloid  $\beta$ -peptide (A $\beta$  1–42) and forms slowly sedimenting A $\beta$  complexes that cause oxidative stress. *Exp. Neurol.* **136**:22–31; 1995.
- [10] Walsh, D. M.; Hartley, D. M.; Kusumoto, Y.; Fezoui, Y.; Condron, M. M.; Lomakin, A.; Benedek, G. B.; Selkoe, D. J.; Teplow, D. B. Amyloid  $\beta$ -protein



- fibrillogenesis: structure and biological activity of protofibrillar intermediates. *J. Biol. Chem.* **274**:25945–25952; 1999.
- [11] Butterfield, D. A.; Lauderback, C. M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid  $\beta$ -peptide-associated free radical oxidative stress. *Free Radical Biol. Med.* **32**:1050–1060; 2002.
- [12] Smith, M. A.; Perry, G.; Pryor, W. A. Causes and consequences of oxidative stress in Alzheimer's disease. *Free Radical Biol. Med.* **32**:1049; 2002.
- [13] Butterfield, D. A.; Galvan, V.; Lange, M. B.; Tang, H.; Sowell, R. A.; Spilman, P.; Fombonne, J.; Gorostiza, O.; Zhang, J.; Sultana, R.; Bredesen, D. E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid  $\beta$ -peptide of APP. *Free Radical Biol. Med.* **48**:136–144; 2010.
- [14] Petersen, R. C. Mild cognitive impairment clinical trials. *Nat. Rev. Drug Discovery* **2**:646–653; 2003.
- [15] Jicha, G. A.; Parisi, J. E.; Dickson, D. W.; Johnson, K.; Cha, R.; Ivnik, R. J.; Tangalos, E. G.; Boeve, B. F.; Knopman, D. S.; Braak, H.; Petersen, R. C. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. *Arch. Neurol.* **63**:674–681; 2006.
- [16] Sultana, R.; Perluigi, M.; Butterfield, D. A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of A $\beta$  in pathogenesis. *Acta Neuropathol.* **118**:131–150; 2009.
- [17] Petersen, R. C. Clinical practice: mild cognitive impairment. *N. Engl. J. Med.* **364**:2227–2234; 2011.
- [18] Calabrese, V.; Cornelius, C.; Mancuso, C.; Barone, E.; Calafato, S.; Bates, T.; Rizzarelli, E.; Kostova, A. T. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. *Front. Biosci.* **14**:376–397; 2009.
- [19] Mancuso, C.; Scapagnini, G.; Curro, D.; Giuffrida Stella, A. M.; De Marco, C.; Butterfield, D. A.; Calabrese, V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. *Front. Biosci.* **12**:1107–1123; 2007.
- [20] Poon, H. F.; Calabrese, V.; Scapagnini, G.; Butterfield, D. A. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. *J. Gerontol. A Biol. Sci. Med. Sci.* **59**:478–493; 2004.
- [21] Maines, M. D. The heme oxygenase system: a regulator of second messenger gases. *Annu. Rev. Pharmacol. Toxicol.* **37**:517–554; 1997.
- [22] Maines, M. D. The heme oxygenase system and its functions in the brain. *Cell. Mol. Biol. (Noisy-le-Grand)* **46**:573–585; 2000.
- [23] Mancuso, C. Heme oxygenase and its products in the nervous system. *Antioxid. Redox Signal.* **6**:878–887; 2004.
- [24] Butterfield, D. A.; Barone, E.; Di Domenico, F.; Cenini, G.; Sultana, R.; Murphy, M. P.; Mancuso, C.; Head, E. Atorvastatin treatment in adog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. *Int. J. Neuropsychopharmacol.* in press Available on CJO 2011. <http://dx.doi.org/10.1017/S1461145711001118>.
- [25] Maines, M. D.; Panahian, N. The heme oxygenase system and cellular defense mechanisms: do HO-1 and HO-2 have different functions? *Adv. Exp. Med. Biol.* **502**:249–272; 2001.
- [26] Stacker, R. Antioxidant activities of bile pigments. *Antioxid. Redox Signal.* **6**:841–849; 2004.
- [27] Mancuso, C.; Barone, E. The heme oxygenase/biliverdin reductase pathway in drug research and development. *Curr. Drug Metab.* **10**:579–594; 2009.
- [28] Salinas, M.; Wang, J.; Rosa de Sagarra, M.; Martin, D.; Rojo, A. I.; Martin-Perez, J.; Ortiz de Montellano, P. R.; Cuadrado, A. Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in vitro and in vivo. *FEBS Lett.* **578**:90–94; 2004.
- [29] Kapitulnik, J.; Maines, M. D. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. *Trends Pharmacol. Sci.* **30**:129–137; 2009.
- [30] Dwyer, B. E.; Nishimura, R. N.; Lu, S. Y. Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody: response to oxidative stress. *Brain Res. Mol. Brain Res.* **30**:37–47; 1995.
- [31] Ewing, J. F.; Weber, C. M.; Maines, M. D. Biliverdin reductase is heat resistant and coexpressed with constitutive and heat shock forms of heme oxygenase in brain. *J. Neurochem.* **61**:1015–1023; 1993.
- [32] Barone, E.; Di Domenico, F.; Cenini, G.; Sultana, R.; Coccia, R.; Preziosi, P.; Perluigi, M.; Mancuso, C.; Butterfield, D. A. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnesic mild cognitive impairment. *J. Alzheimers Dis.* **25**:623–633; 2011.
- [33] Barone, E.; Di Domenico, F.; Cenini, G.; Sultana, R.; Cini, C.; Preziosi, P.; Perluigi, M.; Mancuso, C.; Butterfield, D. A. Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. *Biochim. Biophys. Acta* **1812**:480–487; 2011.
- [34] Hui, Y.; Wang, D.; Li, W.; Zhang, L.; Jin, J.; Ma, N.; Zhou, L.; Nakajima, O.; Zhao, W.; Gao, X. Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. *J. Alzheimers Dis.* **26**:299–313; 2011.
- [35] Schipper, H. M.; Gupta, A.; Szarek, W. A. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. *Curr. Alzheimer Res.* **6**:424–430; 2009.
- [36] McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**:939–944; 1984.
- [37] Cenini, G.; Sultana, R.; Memo, M.; Butterfield, D. A. Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnesic mild cognitive impairment and Alzheimer disease. *Free Radical Biol. Med.* **45**:81–85; 2008.
- [38] Salim, M.; Brown-Kipphut, B. A.; Maines, M. D. Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. *J. Biol. Chem.* **276**:10929–10934; 2001.
- [39] Lerner-Marmarosh, N.; Miralem, T.; Gibbs, P. E.; Maines, M. D. Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. *Proc. Natl. Acad. Sci. USA* **105**:6870–6875; 2008.
- [40] Conrad, C. C.; Talent, J. M.; Malakowsky, C. A.; Gracy, R. W. Post-electrophoretic identification of oxidized proteins. *Biol. Proced. Online* **2**:39–45; 2000.
- [41] Schipper, H. M.; Cisse, S.; Stopa, E. G. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. *Ann. Neurol.* **37**:758–768; 1995.
- [42] Calabrese, V.; Sultana, R.; Scapagnini, G.; Guagliano, E.; Sapienza, M.; Bella, R.; Kanski, J.; Pennisi, G.; Mancuso, C.; Stella, A. M.; Butterfield, D. A. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. *Antioxid. Redox Signal.* **8**:1975–1986; 2006.
- [43] Di Domenico, F.; Sultana, R.; Tiu, G. F.; Scheff, N. N.; Perluigi, M.; Cini, C.; Butterfield, D. A. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnesic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. *Brain Res.* **1333**:72–81; 2010.
- [44] Maines, M. D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. *FASEB J.* **2**:2557–2568; 1988.
- [45] Keller, J. N.; Schmitt, F. A.; Scheff, S. W.; Ding, Q.; Chen, Q.; Butterfield, D. A.; Markesbery, W. R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. *Neurology* **64**:1152–1156; 2005.
- [46] Hensley, K.; Hall, N.; Subramaniam, R.; Cole, P.; Harris, M.; Aksenov, M.; Aksenova, M.; Gabbita, S. P.; Wu, J. F.; Carney, J. M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. *J. Neurochem.* **65**:2146–2156; 1995.
- [47] Markesbery, W. R. Neuropathologic alterations in mild cognitive impairment: a review. *J. Alzheimers Dis.* **19**:221–228; 2010.
- [48] Premkumar, D. R.; Smith, M. A.; Richey, P. L.; Petersen, R. B.; Castellani, R.; Kutty, R. K.; Wiggert, B.; Perry, G.; Kalara, R. N. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. *J. Neurochem.* **65**:1399–1402; 1995.
- [49] Weber, C. M.; Eke, B. C.; Maines, M. D. Corticosterone regulates heme oxygenase-2 and NO synthase transcription and protein expression in rat brain. *J. Neurochem.* **63**:953–962; 1994.
- [50] Chen, Z.; Xu, H.; Haimano, S.; Li, X.; Li, X. M. Quetiapine and venlafaxine synergistically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats. *Neurosci. Lett.* **389**:173–177; 2005.
- [51] Raju, V. S.; McCoubrey Jr. W. K.; Maines, M. D. Regulation of heme oxygenase-2 by glucocorticoids in neonatal rat brain: characterization of a functional glucocorticoid response element. *Biochim. Biophys. Acta* **1351**:89–104; 1997.
- [52] Rauchs, G.; Harand, C.; Bertran, F.; Desgranges, B.; Eustache, F. Sleep and episodic memory: a review of the literature in young healthy subjects and potential links between sleep changes and memory impairment observed during aging and Alzheimer's disease. *Rev. Neurol. (Paris)* **166**:873–881; 2010.
- [53] Green, K. N.; Billings, L. M.; Roozendaal, B.; McLaugh, J. L.; LaFerla, F. M. Glucocorticoids increase amyloid- $\beta$  and tau pathology in a mouse model of Alzheimer's disease. *J. Neurosci.* **26**:9047–9056; 2006.
- [54] Lei, J. K. Change of serum ACTH and cortisol levels in Alzheimer disease and mild cognition impairment. *Zhonghua Yi Xue Za Zhi* **90**:2894–2896; 2010.
- [55] Sapolsky, R. M. Glucocorticoid toxicity in the hippocampus: temporal aspects of neuronal vulnerability. *Brain Res.* **359**:300–305; 1985.
- [56] Sapolsky, R. M.; Pulsinelli, W. A. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. *Science* **229**:1397–1400; 1985.
- [57] Catania, C.; Sotiropoulos, I.; Silva, R.; Onofri, C.; Breen, K. C.; Sousa, N.; Almeida, O. F. The amyloidogenic potential and behavioral correlates of stress. *Mol. Psychiatry* **14**:95–105; 2009.
- [58] Subramaniam, R.; Roediger, F.; Jordan, B.; Mattson, M. P.; Keller, J. N.; Waeg, G.; Butterfield, D. A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. *J. Neurochem.* **69**:1161–1169; 1997.
- [59] Owen, J. B.; Sultana, R.; Aluise, C. D.; Erickson, M. A.; Price, T. O.; Bu, G.; Banks, W. A.; Butterfield, D. A. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for A $\beta$  accumulation in AD brain. *Free Radical Biol. Med.* **49**:1798–1803; 2010.
- [60] Lauderback, C. M.; Hackett, J. M.; Huang, F. F.; Keller, J. N.; Szweda, L. I.; Markesbery, W. R.; Butterfield, D. A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of A $\beta$ 1–42. *J. Neurochem.* **78**:413–416; 2001.
- [61] Takeda, A.; Smith, M. A.; Avila, J.; Nunomura, A.; Siedlak, S. L.; Zhu, X.; Perry, G.; Sayre, L. M. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. *J. Neurochem.* **75**:1234–1241; 2000.
- [62] Barone, E.; Mancuso, C.; Di Domenico, F.; Sultana, R.; Murphy, M. P.; Head, E.; Butterfield, D. A. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. *J. Neurochem.* **120**:135–146; 2011.

- [63] Shibahara, S. The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism. *Tohoku J. Exp. Med.* **200**:167–186; 2003.
- [64] Shibahara, S.; Nakayama, M.; Kitamuro, T.; Uono-Fujimori, R.; Takahashi, K. Repression of heme oxygenase-1 expression as a defense strategy in humans. *Exp. Biol. Med. (Maywood)* **228**:472–473; 2003.
- [65] Brown, S. D.; Piantadosi, C. A. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia. *J. Clin. Invest.* **89**:666–672; 1992.
- [66] Zhang, J.; Piantadosi, C. A. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. *J. Clin. Invest.* **90**:1193–1199; 1992.
- [67] Schipper, H. M.; Bernier, L.; Mehindate, K.; Frankel, D. Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore. *J. Neurochem.* **72**:1802–1811; 1999.
- [68] Williams, T. I.; Lynn, B. C.; Markesbery, W. R.; Lovell, M. A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. *Neurobiol. Aging* **27**:1094–1099; 2006.
- [69] Bradley, M. A.; Xiong-Fister, S.; Markesbery, W. R.; Lovell, M. A. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. *Neurobiol. Aging* **33**:1034–1044; 2012.
- [70] Smith, M. A.; Zhu, X.; Tabaton, M.; Liu, G.; McKeel Jr D. W.; Cohen, M. L.; Wang, X.; Siedlak, S. L.; Dwyer, B. E.; Hayashi, T.; Nakamura, M.; Nunomura, A.; Perry, G. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. *J. Alzheimers Dis.* **19**:363–372; 2010.